News and events coming from the ophthalmic industry
Champion open-water swimmer Gráinne Moss shared resilience lessons from her extreme challenges at the ONZ Business Leaders Forum. She highlighted adaptability, courage, relationships
New Zealand’s first dedicated uveitis conference, Uveitis Aotearoa 2026, will be held 31 July
NZ Optics' latest audience survey highlights the enduring value of trusted industry media, the continued strength of print, and opportunities to evolve digital communication. Respondents
Aspen Pharmacare is expanding its Medsafe registered Eikance atropine eye drop range in NZ to include 0.05% and 0.025% concentrations, offering tailored myopia control for children aged 4-14 years.
England and Chelsea goalkeeper Hannah Hampton, diagnosed with strabismus at birth and later impaired depth perception, achieved an elite football career thanks to early eyecare and multiple surgeries. She now advocates for eye health awareness.
A UK multicentre trial found daily 0.01% atropine eye drops significantly reduced myopia progression and eye growth in children compared to
Scientists developed brain-stimulating contact lenses that produced antidepressant-like effects comparable to fluoxetine (Prozac) in a mouse model of depression
A new version of the WCO Alcon Dry Eye Wheel features the latest recommendations from the TFOS DEWS III report
An AI-assisted audit found nearly 3,000 peer-reviewed biomedical papers contain fabricated references, with the rate growing significantly. This
NZ Optics is pleased to announce the winner of our recent Readership Survey prize draw.
A large retrospective study found early antiviral treatment for Covid‐19, such as Paxlovid, is associated with a reduced risk of uveitis.
In the UK, a six-year-old girl’s sight has improved following Luxturna (voretigene neparvovec) treatment in both eyes for RPE65-related Leber congenital amaurosis (LCA).